Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Study of microRNAs in a Decompensated Cirrhosis

A legfontosabb adatok

Ki végzi
Hospices Civils de Lyon
Hol
Franciaország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
444 fő, tervezett
Kezdés
2019. jún. 26.
Várható befejezés
2034. jún. 26.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • blood sample at Day 0
  • blood sample at Day 2 and Day 7
  • stool sample at Day 0
A regiszteradat frissítve
2025. június 18.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with cirrhosis (liver scarring). Some were admitted within 48 hours for a sudden worsening, others have stable cirrhosis and are followed as outpatients.

Életkor
18 Years and older
Nem
All sexes
A betegség stádiuma
Cirrhosis, confirmed by a tissue test or by clinical and imaging signs. Either a sudden worsening (for example jaundice, confusion from liver disease, fluid in the belly, gut bleeding, kidney failure, low sodium or worse liver function) with admission within 48 hours, or stable cirrhosis with no hospital stay for a sudden worsening in the last 6 months.

A részvétel fő kizáró okai

  • Pregnant women
  • People under guardianship or curatorship, or deprived of liberty
  • Past cancer outside the digestive system, or past liver or bile duct cancer
  • Chronic hepatitis B, or hepatitis C now or treated successfully less than 6 months ago
  • HIV infection found by a blood test in the last 6 months

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with cirrhosis (determined either by histopathology or by association of clinical signs of portal hypertension and hepatocellular insufficiency and radiological signs (dysmorphic liver, evidences of portal hypertension (collateral circulation, ascites)); AND
  • Not refusing his / her participation in the study after information (or non-opposition of the person of confidence if the patient has a disorder of consciousness or impaired judgment (hepatic encephalopathy) at the time of inclusion) AND
  • Admitted within 48 hours for an episode of acute decompensation (acute decompensation group = AD group), which is defined by the sudden occurrence of one or more of the following clinical or biological symptoms:; Jaundice; Hepatic encephalopathy; oedemato-ascitic decompensation; Gastro-intestinal bleeding; Acute renal failure (according to AKIN criteria (22)) and / or hyponatremia; Degradation of hepatocellular functions (decrease of prothrombin time and factor V measured in blood, increase of bilirubinemia) OR
  • Outpatient follow-up for stable cirrhosis, not admitted in the last 6 months for an episode of acute cirrhosis decompensation (pathological control group)

Ki nem vehet részt

  • History of extra-digestive cancer
  • History of hepatocellular carcinoma or other hepatobiliary cancer
  • Chronic infection with Hepatitis B virus (defined by the presence of Antibodies to hepatitis B core antigen (anti-HBc) and the absence of Hepatitis B surface antibodies (anti-HBs)) identified by a recent serology (less than 6 months)
  • Chronic Hepatitis C Virus infection or cured for less than 6 months
  • Infection with the Human Immunodeficiency Virus identified by a recent serology (less than 6 months)
  • Minor or major patient under guardianship or curatorship
  • Pregnant women
  • Patient deprived of liberty

Ez a vizsgálat jelenleg itt érhető el: Franciaország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Cirrhotic patients are at higher risk of sepsis due to impaired innate and adaptive immune responses. Septic complications represent a major issue in the management of cirrhotic patients, with a 1-month mortality rate of 23%, which increases to 80% at 3 months in case of associated organ failure.

A teljes eredeti leírásKevesebb

Delay to treatment initiation during a septic episode may increase the risk of complications and mortality of cirrhotic patients. However, the inappropriate use of antibiotics exposes cirrhotic patients to the risk of more severe infections due to multi-resistant organisms or fungi.

The use of diagnostic markers for sepsis is limited in the context of cirrhosis because of the lack of hepatic synthesis of these markers on the one hand and non-specific inflammation related to cirrhosis on the other hand.

Therefore, it is necessary to develop new tools for the early diagnosis of sepsis and appropriate management of cirrhotic patients.

The interest of microRNAs (miRNAs) in the diagnosis and prognosis of septic shock has been reported in the general population. No studies have described circulating miRNAs or reported their interest in the diagnosis of sepsis in a population of cirrhotic patients with acute decompensation (AD).

This preliminary study of 800 circulating miRNAs will be performed in a cohort of patients with acute cirrhosis decompensation, for whom the incidence of sepsis is estimated at 40%. The aim to evaluate the interest and feasibility of a larger study on the interest of circulating miRNAs in the early diagnosis of sepsis in cirrhotic patients. The long-term objective of this study is the development of biomarkers for the early management of cirrhotic patients with sepsis and the rationalization of antibiotic use to improve their prognosis.

A vizsgálat 2 csoportja

  • acute decompensation group

    patients admitted within 48 hours for acute decompensation of cirrhosis, with or without evidence of sepsis

    Kezelés: blood sample at Day 0, blood sample at Day 2 and Day 7 és stool sample at Day 0

  • Pathological control group

    patients with Chronic Liver Disease (CLD), also named stable cirrhotic patients, without any admission in the last 6 months for an acute event

    Kezelés: blood sample at Day 0 és stool sample at Day 0

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Expression and Variance of microRNAs in a Cohort of Patients With Acute Decompensation of Cirrhosis.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. június 18.